Brief: Nurix Therapeutics To Report Updated Phase 1A/B Results For Btk Degrader Bexobrutideg, Highlighting Durable Responses In Relapsed/Refractory Cll/Sll And Promising Activity In Earlier Lines Of Therapy
BRIEF-Nurix Therapeutics To Report Updated Phase 1A/B Results For Btk Degrader Bexobrutideg, Highlighting Durable Responses In Relapsed/Refractory Cll/Sll And Promising Activity In Earlier Lines Of Therapy June 11 (Reuters) - Nurix Therapeutics Inc NRIX.O:
NURIX THERAPEUTICS TO REPORT UPDATED PHASE 1A/B RESULTS FOR BTK DEGRADER BEXOBRUTIDEG, HIGHLIGHTING DURABLE RESPONSES IN RELAPSED/REFRACTORY CLL/SLL AND PROMISING ACTIVITY IN EARLIER LINES OF THERAPY
NURIX THERAPEUTICS - REPORTS 92.9% OBJECTIVE RESPONSE RATE IN SECOND LINE BTKI-EXPOSED, BCL2I-NAÏVE CLL PATIENTS
NURIX THERAPEUTICS - PHASE 1A DATA SHOWS 22.1 MONTH MEDIAN PFS, 83% ORR IN HEAVILY PRETREATED RELAPSED/REFRACTORY CLL/SLL
NURIX THERAPEUTICS - BEXOBRUTIDEG WELL TOLERATED WITH CONSISTENT SAFETY PROFILE
NURIX THERAPEUTICS - RESPONSES OBSERVED IN HIGH-RISK, BTK RESISTANT, AND CNS-INVOLVED CLL SUBGROUPS
Source text: ID:nGNX6Z6fqX
Further company coverage: NRIX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nurix Therapeutics
See all newsNurix Therapeutics Q3 swings to profit on Roche collaboration
Brief: Nurix Extends Gilead Collaboration For Oncology Program
Commercialize Potential Best-In-Class Btk Degrader Bexobrutideg Across Malignant Hematology, Immunology And Neurology
Nurix Therapeutics Q2 revenue falls sharply, net loss widens; strikes up to $2.3 bln collab with Roche
U.S. RESEARCH ROUNDUP- Datadog, Jabil, Prologis